6-[5-ethyl-2-methoxy-4-(piperidin-4-yl-oxy)-phenyl]-pyridin-2-yl-amine | 1019636-83-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 6-[5-ethyl-2-methoxy-4-(piperidin-4-yl-oxy)-phenyl]-pyridin-2-yl-amine
• 英文别名: 6-(5-Ethyl-2-methoxy-4-piperidin-4-yloxyphenyl)pyridin-2-amine
• CAS: 1019636-83-9
• 化学式: C₁₉H₂₅N₃O₂
• 分子量: 327.426
• InChiKey: SWTJUTMEEFYPLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  69.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
  申请人：Pfizer Inc.

  公开号：US20030162765A1

  公开（公告）日：2003-08-28

  This present invention relates to compounds of the formula 1 wherein G, R 1 and R 2 are defined as in the specification, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.

  本发明涉及公式1的化合物，其中G、R1和R2如规范中所定义，以及含有它们的制药组合物，以及它们在治疗和预防中枢神经系统和其他疾病方面的用途。
• Modulators of CDC2-like kinases (CLKS) and methods of use thereof
  申请人：Milne Jill

  公开号：US20070248590A1

  公开（公告）日：2007-10-25

  Provided herein are methods for using Cdc2-like kinase (Clk) modulators for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, ocular disorders, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a Clk modulating compound in combination with another therapeutic agent.

  本文提供了使用Cdc2-like kinase (Clk)调节剂治疗和/或预防各种疾病和障碍的方法，包括与衰老或压力有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症、眼部疾病和/或潮红，以及需要增加线粒体活动的疾病或障碍。此外，提供了包含Clk调节化合物与另一种治疗剂联合使用的组合物。
• SIRTUIN MODULATING COMPOUNDS
  申请人：Nunes Joseph J.

  公开号：US20120197013A1

  公开（公告）日：2012-08-02

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新颖的调节沉默信息调节因子（sirtuin）的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞寿命，并用于治疗和/或预防多种疾病和障碍，包括与衰老或应激有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗药物组合的组合物。
• Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
  申请人：GlaxoSmithKline Intellectual Property (No. 2) Limited

  公开号：US10485814B2

  公开（公告）日：2019-11-26

  Provided herein are stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride, and pharmaceutical compositions and uses thereof. The stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride may be used to treat a disease or disorder that would benefit from increased NAD levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, obesity, for increasing insulin sensitivity in a subject, or to treat or prevent a skin condition. The compounds have general formulas (I) or (II): wherein R1 is —C(═O)—X—(C2-C18 straight chain or branched) alkyl or —C(═O)—X—(C2-C18 straight chain or branched) alkenyl; each R2 is independently selected from hydrogen, and a —C(O)—X—(C1-C18 straight chain or branched) alkyl or a —C(O)—X—(C2-C18 straight chain or branched) alkenyl; and X is a covalent bond or O.

  本文提供了烟酰胺核糖苷和烟酰胺核糖苷氢化物的立体异构纯酯和碳酸酯类似物及其药物组合物和用途。烟酰胺核糖苷和烟酰胺核糖苷氢化物的立体异构纯酯和碳酸酯类似物可用于治疗因 NAD 水平升高而获益的疾病或紊乱，包括线粒体疾病或紊乱、胰岛素抵抗、代谢综合征、糖尿病、肥胖症，以提高受试者的胰岛素敏感性，或治疗或预防皮肤病。 这些化合物具有通式（I）或（II）： 其中 R1 是-C(═O)-X-(C2-C18 直链或支链)烷基或-C(═O)-X-(C2-C18 直链或支链)烯基；每个 R2 独立地选自氢、-C(O)-X-(C1-C18 直链或支链)烷基或-C(O)-X-(C2-C18 直链或支链)烯基；以及 X 是共价键或 O。
• Pharmaceutical combinations for the treatment of neurodegenerative diseases
  申请人：Pfizer, Inc.

  公开号：US20030045449A1

  公开（公告）日：2003-03-06

  This invention relates to methods of treating neurodegenerative diseases, comprising administering to a patient in need of such treatment an N-NOS inhibitor in combination with either: (a) NMDA receptor antagonist; (b) a sodium channel antagonist; (c) an acetylcholine esterase inhibitor; (d) a dopamine agonist; (e) a potassium channel opener; (f) an AMPA/kainate receptor antagonist; (g) a calcium channel antagonist; (h) a GABA-A receptor modulator (e.g., a GABA-A receptor agonist); (i) TPA (j) matrix-metalloprotease inhibitor or (k) L-Dopa. The pharmaceutical compounds are also disclosed.

  本发明涉及治疗神经退行性疾病的方法，包括向需要此类治疗的患者施用 N-NOS 抑制剂与以下任一种药物的组合：(a) NMDA 受体拮抗剂；(b) 钠通道拮抗剂；(c) 乙酰胆碱酯酶抑制剂；(d) 多巴胺激动剂；(e) 钾通道开启剂；(f) AMPA/kainate 受体拮抗剂；(g) 钙通道拮抗剂；(h) GABA-A 受体调节剂（例如g.,(i) TPA (j) 基质金属蛋白酶抑制剂或 (k) 左旋多巴。还公开了药物化合物。